Safety Constraints in an Artificial Pancreatic β Cell: An Implementation of Model Predictive Control with Insulin on Board

Ограничения безопасности в искусственной β-клетке поджелудочной железы: реализация управления с прогнозирующей моделью с учетом активного инсулина
Howard Zisser, Eyal Dassau, Francis J. Doyle, Benyamin Grosman, Lois G. Jovanovic, Christian Ellingsen, Matthew W. Percival
2009-05-01

artificial pancreatic beta cellautomated insulin deliveryhypoglycemia preventioninsulin on boardmodel predictive control
BACKGROUND: Type 1 diabetes mellitus (T1DM) is characterized by the destruction of pancreatic beta cells, resulting in the inability to produce sufficient insulin to maintain normoglycemia. As a result, people with T1DM depend on exogenous insulin that is given either by multiple daily injections or by an insulin pump to control their blood glucose. A challenging task is to design the next step in T1DM therapy: a fully automated insulin delivery system consisting of an artificial pancreatic beta cell that shall provide both safe and effective therapy. The core of such a system is a control algorithm that calculates the insulin dose based on automated glucose measurements. METHODS: A model predictive control (MPC) algorithm was designed to control glycemia by controlling exogenous insulin delivery. The MPC algorithm contained a dynamic safety constraint, insulin on board (IOB), which incorporated the clinical values of correction factor and insulin-to-carbohydrate ratio along with estimated insulin action decay curves as part of the optimal control solution. RESULTS: The results emphasized the ability of the IOB constraint to significantly improve the glucose/insulin control trajectories in the presence of aggressive control actions. The simulation results indicated that 50% of the simulations conducted without the IOB constraint resulted in hypoglycemic events, compared to 10% of the simulations that included the IOB constraint. CONCLUSIONS: Achieving both efficacy and safety in an artificial pancreatic beta cell calls for an IOB safety constraint that is able to override aggressive control moves (large insulin doses), thereby minimizing the risk of hypoglycemia.
1
A model predictive control algorithm was developed for automated insulin delivery in an artificial pancreatic beta cell.
2
An insulin-on-board constraint can override excessively large insulin doses, reducing hypoglycemia risk while supporting effective glycemic control.
3
Hypoglycemic events occurred in 50% of simulations without the constraint, compared with 10% when it was included.
4
The controller incorporated insulin on board as a dynamic safety constraint using correction factors, insulin-to-carbohydrate ratios, and estimated insulin action decay curves.
5
The insulin-on-board constraint significantly improved glucose and insulin trajectories during aggressive control actions.

artificial pancreatic β-cell system for automated exogenous insulin delivery in people with type 1 diabetes mellitus

the safety and effectiveness of model-predictive glycemic control using an insulin-on-board constraint to limit aggressive insulin dosing and reduce hypoglycemia

Publication Details
Publication Date
2009-05-01
Journal
Publisher
ISSN
Cited by
154
Access Type
Author Information
Authors
Howard Zisser
Eyal Dassau
Francis J. Doyle
Benyamin Grosman
Lois G. Jovanovic
Christian Ellingsen
Matthew W. Percival
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%